Juno Therapeutics Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Juno Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Juno Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Juno Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Fifty Two Week Low | 85.47 | |
| Fifty Two Week High | 85.87 |
Juno |
Juno Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.00 in Juno Therapeutics on January 24, 2024 and sell it today you would earn a total of 0.00 from holding Juno Therapeutics or generate 0.0% return on investment over 90 days. Juno Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Juno, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Juno Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Juno Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Juno Therapeutics, and traders can use it to determine the average amount a Juno Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| JUNO |
Based on monthly moving average Juno Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Juno Therapeutics by adding Juno Therapeutics to a well-diversified portfolio.
Juno Therapeutics Fundamentals Growth
Juno Stock prices reflect investors' perceptions of the future prospects and financial health of Juno Therapeutics, and Juno Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Juno Stock performance.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (342.91) % | |||
| Current Valuation | 8.92 B | |||
| Shares Outstanding | 116.11 M | |||
| Price To Earning | (15.21) X | |||
| Price To Book | 8.60 X | |||
| Price To Sales | 94.75 X | |||
| Revenue | 106.56 M | |||
| EBITDA | (350.85 M) | |||
| Cash And Equivalents | 927.53 M | |||
| Cash Per Share | 8.18 X | |||
| Total Debt | 10.01 M | |||
| Debt To Equity | 0.80 % | |||
| Book Value Per Share | 14.11 X | |||
| Cash Flow From Operations | (201.61 M) | |||
| Earnings Per Share | (3.39) X | |||
| Total Asset | 1.45 B | |||
| Retained Earnings | (726.68 M) | |||
| Current Asset | 951.84 M | |||
| Current Liabilities | 119.73 M |
Things to note about Juno Therapeutics performance evaluation
Checking the ongoing alerts about Juno Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Juno Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Juno Therapeutics is not yet fully synchronised with the market data | |
| Juno Therapeutics has some characteristics of a very speculative penny stock | |
| Juno Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 106.56 M. Net Loss for the year was (353.85 M) with profit before overhead, payroll, taxes, and interest of 111.87 M. | |
| Juno Therapeutics currently holds about 927.53 M in cash with (201.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.18. | |
| Over 81.0% of the company shares are owned by institutional investors |
- Analyzing Juno Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Juno Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Juno Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Juno Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Juno Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Juno Therapeutics' stock. These opinions can provide insight into Juno Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Juno Stock
If you are still planning to invest in Juno Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Juno Therapeutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |